• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

PNR Weekly Digest: April 6, 2021
Items regarding COVID-19 information are indicated with an * In the Dragonfly: Understanding End-of-Life Matters Whether your focus of concern is on a family member or yourself, this April the NNLM Reading Club suggests three books that may help with your understanding of end-of-life matters and those conversations you probably have been putting off…read the post to see the book selections Professional Development: NNLM CE Opportunities: NNLM offers training on a variety of topics related to health information. A complete listing of NNLM educational opportunities is available. Please note you need to create an NNLM accou...
Source: Dragonfly - April 6, 2021 Category: Databases & Libraries Authors: Carolyn Martin Tags: PNR Weekly Digest Source Type: news

February Partner Spotlight
The Texas Diabetes Prevention and Control Program Incorporates NDEP Messages and Materials in its “Get Tested Today” Campaign The Texas Diabetes Prevention and Control Program (DPCP) at the Texas Department of State Health Services administers grant-funded initiatives and contracted services to address current issues affecting people with diabetes and those at risk of getting diabetes. The Texas DPCP maintains a statewide system of quality education services for all people with diabetes and health care professionals who offer diabetes treatment and educa...
Source: National Diabetes Education Program - January 31, 2014 Category: Endocrinology Source Type: news